Shannon Tumblin
Family · Coupeville, WANPI 1376166884
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $614 of the $695 with a category attached, or 88.4%. 10 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 27.8% of the total. Reporting peaked in 2024 at $243 and has fallen 51.8% since, to $117 in 2025.
Across 25 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$193
- Organogenesis Inc.$114
- UCB, Inc.$97
- E.r. Squibb & Sons, L.L.C.$93
- Smith+Nephew$52
- Sun Pharmaceutical Industries Inc.$50
- plus $96 from 4 others
What the payments were for
- Food & beverage$61488%
- Education$8112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $193 |
| Organogenesis Inc. | 2 | $114 |
| UCB, Inc. | 4 | $97 |
| E.r. Squibb & Sons, L.L.C. | 4 | $93 |
| Smith+Nephew | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 3 | $50 |
| AbbVie | 2 | $39 |
| Amgen | 1 | $22 |
| Sensus Healthcare, Inc. | 1 | $20 |
| KCI USA, Inc. | 1 | $15 |
How this compares
$695 in reported general payments places this provider in the 75th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 122 | $4,658 |
| Fluorouracil | 35 | $2,530 |
| Ketoconazole | 120 | $1,965 |
| Metronidazole | 28 | $1,852 |
| Desonide | 19 | $1,579 |
| Doxycycline Hyclate | 53 | $1,000 |
| Triamcinolone Acetonide | 110 | $976 |
| Clindamycin Phosphate | 21 | $549 |
| Ciclopirox | 14 | $536 |
| Mupirocin | 51 | $525 |
| Imiquimod | 15 | $348 |
| Ammonium Lactate | 13 | $316 |
| NyamycNystatin | 11 | $267 |
| Hydrocortisone | 41 | $252 |
| ValacyclovirValacyclovir Hcl | 15 | $173 |
Paid to pharmacies, not to this prescriber.
Other family in Coupeville
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
- Brittanee WorthySpokane Valley$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.